In our breast cancer trial with oral Maitake beta-glucan [25], we assessed circulating levels of G-CSF in a subset of 6 patients comparing double baseline levels with 3 follow-up visits over a 12-week period. The gene discussed is CSF3; the disease is breast carcinoma.